Sponsor
Nancy Mace
Representative · R-SC
Representative · R-SC
This bill aims to clarify and standardize VA policy and pilot the use of peptide therapies—potentially expanding evidence-based treatment options for veterans and improving consistency of care—while creating administrative burdens, risking near-term access limits depending on definitions and pilot design, and possibly increasing VA/taxpayer costs if therapies are adopted broadly.
Veterans will have a clearer, officially defined meaning of "peptide" and what counts as peptide-based therapy, reducing confusion about eligibility and coverage for VA treatments.
VA clinicians and medical centers will receive consistent regulatory guidance and standardized clinical protocols for peptide therapies, improving treatment decisions and more uniform, evidence-based care across the VA system.
If peptide therapies are effective, veterans could gain access to new treatment options that improve recovery, chronic pain, mental health, or rehabilitation outcomes.
Taxpayers and the VA could face substantial new costs if peptide therapies are adopted broadly—covering treatment expenses and program implementation—without specified funding offsets.
A volunteer-only, geographically or clinically limited pilot plus an inconclusive underlying evidence base could delay access for many veterans and consume VA resources while producing results that aren't generalizable.
If the Secretary adopts a narrow definition of "peptide," some veterans may lose access to therapies previously treated as peptide-based until policy is revised, causing immediate coverage disruptions.
Based on analysis of 3 sections of legislative text.
Directs VA to define peptides, study peptide-based therapies for veterans, report findings, and—if appropriate—run a volunteer pilot program.
Official title: To direct the Secretary of Veterans Affairs to study the potential benefits of peptide-based therapies for veterans receiving care through the Department of Veterans Affairs, and for other purposes.
Introduced September 1, 2026 by Nancy Mace · Last progress September 1, 2026
Requires the Department of Veterans Affairs to define “peptide” and “peptide-based therapy,” review existing VA rules and recent research, and report those definitions and findings to Congress within 180 days. After that report, the VA must complete an 18-month study on the safety, efficacy, and potential uses of peptide therapies for veterans, report recommendations to Congress, and—if appropriate—stand up a limited pilot program for volunteer veterans and report on its results within five years.